Dow Falls Again on Fed Worries

After a middling opening, the Dow Jones Industrial Average (DJINDICES: ^DJI  ) fell in the afternoon on -- surprise, surprise -- murmurs that the Federal Reserve will begin scaling back its stimulus program sooner than some investors had hoped. On the day, the blue chips ended the day down 76 points, or 0.5%. Today it was the Kansas City Fed President Esther George's turn, as she spoke out against more stimulus, saying once again that continued bond-buying was only inflating markets. Another Fed official also said changes could be coming soon to the $85 billion monthly bond-buying program. Still, the Dow was able to rebound from a session low of 1% down.

Turning to individual stocks, Home Depot (NYSE: HD  ) led the Dow's fall, dropping 2.6%, though there was no particular news affecting the home-improvement retailer. Home Depot shares were probably brought down by concerns about the Fed cutbacks, as the stock has been on a tear over the last year, increasing by more than 50%, and nearly tripling in the past two years as the strengthening housing market has fueled its recovery. Still, with a P/E over 24 and a general sentiment that the market is peaking, investors may have simply taken the opportunity to grab some juicy profits.

Merck (NYSE: MRK  ) , meanwhile, was a strong performer for the second day in a row, gaining 2% on the day. Today's gains simply seem to have carried over from yesterday's announcement that the drugmaker has made a potential breakthrough with a melanoma drug, as recent results showed that it helped reduce tumors in more than half of patients who took the maximum allowable dosage. My colleague Dan Caplinger also believes that the discovery could lead to several other new drugs, because of its ability to stimulate the PD-1 protein.

AT&T (NYSE: T  ) was another strong gainer today, rising 1.7%. Last night, the telecom announced a plan with IBM (NYSE: IBM  ) to develop more network-efficient apps. The company said that "the new technology enables enterprise to conduct comprehensive testing of their networks' battery usage on mobile devices." The partnership could also bear more fruit down the road, as AT&T stands to benefit from a variety of applications of IBM's technology.

Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, The Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.



Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2472049, ~/Articles/ArticleHandler.aspx, 4/24/2014 5:38:08 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement